CD274 and neoplasm: Since PD-L1 is not only a tumor antigen but also a proven immune checkpoint for cancer immunotherapy, the PD-L1 arm of HK010 was screened to block the PD-1/PD-L1 interaction, which was confirmed by crystallography and in vitro bioassays.